CA3120102A1 - Engineered cd25 polypeptides and uses thereof - Google Patents

Engineered cd25 polypeptides and uses thereof Download PDF

Info

Publication number
CA3120102A1
CA3120102A1 CA3120102A CA3120102A CA3120102A1 CA 3120102 A1 CA3120102 A1 CA 3120102A1 CA 3120102 A CA3120102 A CA 3120102A CA 3120102 A CA3120102 A CA 3120102A CA 3120102 A1 CA3120102 A1 CA 3120102A1
Authority
CA
Canada
Prior art keywords
antibody
engineered
engineered polypeptide
binding
fold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3120102A
Other languages
English (en)
French (fr)
Inventor
Matthew P. Greving
Phung Tu GIP
Mohan Srinivasan
Andrew Morin
Kevin Eduard HAUSER
Jordan R. WILLIS
Cody A. MOORE
Christian Barrett
Alex T. TAGUCHI
Angeles Estelles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ibio Inc
Original Assignee
Rubryc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubryc Therapeutics Inc filed Critical Rubryc Therapeutics Inc
Publication of CA3120102A1 publication Critical patent/CA3120102A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3120102A 2018-11-14 2019-11-14 Engineered cd25 polypeptides and uses thereof Pending CA3120102A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862767431P 2018-11-14 2018-11-14
US62/767,431 2018-11-14
US201962902334P 2019-09-18 2019-09-18
US62/902,334 2019-09-18
PCT/US2019/061567 WO2020102603A1 (en) 2018-11-14 2019-11-14 Engineered cd25 polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CA3120102A1 true CA3120102A1 (en) 2020-05-22

Family

ID=70731914

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3120102A Pending CA3120102A1 (en) 2018-11-14 2019-11-14 Engineered cd25 polypeptides and uses thereof

Country Status (6)

Country Link
US (1) US12441803B2 (https=)
EP (1) EP3880698A4 (https=)
JP (3) JP7695881B2 (https=)
CN (1) CN113646330A (https=)
CA (1) CA3120102A1 (https=)
WO (1) WO2020102603A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
EP3880227A4 (en) 2018-11-14 2022-11-09 RubrYc Therapeutics, Inc. ANTI-CD25 ANTIBODIES
JP7579812B2 (ja) * 2019-05-31 2024-11-08 アイバイオ， インク． メソスケールペプチドを操作するための機械学習ベースの装置およびそのための方法およびシステム
WO2021119261A1 (en) * 2019-12-10 2021-06-17 Homodeus, Inc. Generative machine learning models for predicting functional protein sequences
MX2023005032A (es) * 2020-11-10 2023-05-16 Scripps Research Inst Anticuerpos para tratamientos con opioides.
WO2022119863A1 (en) * 2020-12-01 2022-06-09 Rubryc Therapeutics, Inc. Generalized scaffolds for polypeptide display and uses thereof
US20250179196A1 (en) * 2021-07-30 2025-06-05 Janssen Biotech, Inc. Materials and methods of making or using il-23r binding proteins
CN114384245B (zh) * 2022-03-24 2022-06-24 江苏美克医学技术有限公司 新型冠状病毒s-rbd蛋白和n蛋白双表位识别的联检试剂盒及其应用
WO2025235413A1 (en) * 2024-05-05 2025-11-13 Duke University Compositions targeting cancer antigens and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1279057C (zh) * 2002-07-12 2006-10-11 马菁 重组的抗cd25单克隆抗体、其编码序列及应用
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
US8586709B2 (en) 2007-09-25 2013-11-19 Pastoral Greenhouse Research Limited Cell-permeabilising peptides and polypeptides for microbial cells
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EP2970398B1 (en) * 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3191121B1 (en) * 2014-09-10 2020-05-27 The University of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
US10377815B2 (en) 2015-05-05 2019-08-13 Albert Einstein College Of Medicine Bispecific antibodies and fusion proteins that bind to EBOV and NPC1
WO2018089829A1 (en) * 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
EP3612565A4 (en) * 2017-04-18 2021-06-16 R-Pharm Overseas, Inc. ANTI-PD-L1 ANTIBODIES AND USES THEREOF
PE20210313A1 (es) * 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
EP3880227A4 (en) 2018-11-14 2022-11-09 RubrYc Therapeutics, Inc. ANTI-CD25 ANTIBODIES
JP7579812B2 (ja) 2019-05-31 2024-11-08 アイバイオ， インク． メソスケールペプチドを操作するための機械学習ベースの装置およびそのための方法およびシステム

Also Published As

Publication number Publication date
JP7695881B2 (ja) 2025-06-19
JP2026065087A (ja) 2026-04-14
JP2025026923A (ja) 2025-02-26
CN113646330A (zh) 2021-11-12
JP2022513043A (ja) 2022-02-07
EP3880698A4 (en) 2022-11-30
US20230016112A1 (en) 2023-01-19
WO2020102603A1 (en) 2020-05-22
EP3880698A1 (en) 2021-09-22
US12441803B2 (en) 2025-10-14

Similar Documents

Publication Publication Date Title
US12441803B2 (en) Engineered CD25 polypeptides and uses thereof
JP7206303B2 (ja) 可変ドメインｖｌおよびｖｈｈ誘導体に基づく高アフィニティおよび凝集耐性抗体
AU2008267733B2 (en) Sequence based engineering and optimization of single chain antibodies
EP2050765B1 (en) Methods for use in human-adapting monoclonal antibodies
EP2890711B1 (en) Method for producing antibody molecules having inter-species, intra-target cross-reactivity
US20220081472A1 (en) Meso-scale engineered peptides and methods of selecting
CN114746440A (zh) 新型多肽复合物
KR20170070070A (ko) Vh-vl-도메인간 각도 기반 항체 인간화
Al Qaraghuli et al. Analysis of the binding loops configuration and surface adaptation of different crystallized single‐domain antibodies in response to various antigens
Almagro et al. Characterization of a high‐affinity human antibody with a disulfide bridge in the third complementarity‐determining region of the heavy chain
AU2015364687A1 (en) Intercalated single-chain variable fragments
WO2022037527A1 (zh) 结合bcma的单可变结构域及抗原结合分子
JP6889328B2 (ja) 三次元構造に基づくヒト化方法
CN118702814A (zh) 一种抗ngf单克隆抗体及其应用
JP7691234B2 (ja) 抗体の抗原に対する親和性を向上させる方法及びその利用
JP2024523921A (ja) 特異的バインダーの選択手段及び方法
HK40063514A (en) Engineered cd25 polypeptides and uses thereof
CN101426526B (zh) 使用工程诱杀蛋白的液相生物淘选方法
CN110407942B (zh) 针对kn044的单域抗体
Rodríguez Gómez et al. Generation and NGS profiling of naïve rabbit antibody libraries for efficient monoclonal antibody selection
CN117836308A (zh) 用于选择特异性结合剂的手段和方法
JP2025508603A (ja) ネコ抗体ライブラリー
HK40076302A (en) New polypeptide complex
Gilliland Engineering antibody therapeutics Mark L Chiu and Gary L Gilliland
Pszolla Computational design of novel interactions in conventional and heavy chain antibodies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231113

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241003

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241003

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241003

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250207

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250609

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250610

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250728

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250728

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250924

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250924

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P145 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - DEFECT(S)

Effective date: 20251223